key: cord-0796005-vd1sydjv
authors: Tarantino, Nicola; Della Rocca, Domenico G.; Zou, Fengwei; Lin, Aung; Natale, Andrea; Di Biase, Luigi
title: Prevalence, Outcomes, and Management of Ventricular Arrhythmias in COVID-19 Patients
date: 2021-10-29
journal: Card Electrophysiol Clin
DOI: 10.1016/j.ccep.2021.10.002
sha: b32fb5e2b928f4f05e12383b21e8c992417e9aae
doc_id: 796005
cord_uid: vd1sydjv

We review the current data on epidemiology, the clinical significance, the pathophysiologic mechanisms, and the treatment of VAs in the setting of COVID-19. VAs prevail in 0.15-8% of in hospitalized patients, but only sustained and rapid tachyarrhythmias are purportedly associated with a significant increase in mortality. Multiple factors can elicit VAs, which are ultimately deemed to be a marker of severe systemic disease rather than a distinct cardiac condition. Even though the electrophysiologist plays a determinant role in the secondary prevention of VAs, a multidisciplinary approach is indispensable for primary prophylaxis and acute management.

At the time of writing the present chapter, SARS-CoV-2, aka COVID-19, has reportedly hit almost 180 million people globally in less than 18 months since its official identification and disclosure as pandemic. 1 Initially announced as a severe acute respiratory syndrome due to a novel strain of coronavirus, after the acronym SARS-2-CoV-2, the first pandemic of the third millennium was unexpectedly far from being an isolated respiratory condition. Instead, a multitude of signs and symptoms, sometimes representing the only atypical manifestation of the disease, have been described with alacrity, making the COVID-19 indeed configuring as a systemic disease requiring a multidisciplinary care.

Pertaining the cardiovascular complications or manifestations of the SARS-CoV-2, in the present chapter we offer an overview of the ventricular arrhythmias related to acute COVID-19 infections, discussing the prevalence, the possible mechanisms due to direct or indirect virus involvement, and the currently proposed therapeutic options.

Mitacchione and colleagues described the first case of ventricular storm (12 episodes of sustained ventricular tachycardias, VT) with concomitant COVID-19 infection in a patient with defibrillator (ICD) and ischemic cardiomyopathy (ejection fraction= 34%) admitted to an Italian hospital for respiratory distress. 2 ICD interrogation showed sustained and non-sustained monomorphic VTs in the days before the admission. The authors excluded iatrogenic causes because the systemic use of QT-prolonging immunomodulators and antimicrobials was not recommended at that time, and the VT was probably due to other mechanisms (see paragraph 4). This insightful report suggests that VAs could be the first sign of latent infection in susceptible patients with structural heart disease (SHD).

In addition, two descriptions of PMVT (polymorphic ventricular tachycardia) in the settings of prolonged and normal QT respectively were also reported. 3, 4 Of interest two separate cases of newly diagnosed Brugada syndrome were reported, one presenting as an asymptomatic coved-type pattern during febrile peak, 5 and the other as PMVT due to fever and drug-induced bradycardia. 6 J o u r n a l P r e -p r o o f

The overall prevalence of VAs in COVID-19 patients ranges between 0.15% and 8% (Table 1) . 7, 8 Such a discrepancy stems from the definition of VAs and subpopulations analyzed. The first series by Guo showed that malignant arrhythmias were relatively more common in patients with cardiac injury-defined as troponin T elevation-(11% vs. 5% over a total of 187 individuals). 8 A retrospective study of 700 patients differentiates the prevalence between patients admitted to intensive care unit (ICU) compared to non-intensive care settings. 7 In total, only one patient had a life-threatening torsade de pointes (TdP) in ICU (1.4% vs. none in the comparison group).

Similarly, non-sustained episodes were more common in critical patients (8% vs. 0.6%). In line with this analysis, a Scandinavian group observed that incidence of VAs in ICU patients was about 3% (n= 2/155) 9 , yet, according to a larger cohort of 1053 hospitalized patients, non-sustained episodes are far less prevalent than malignant VAs (0.7% vs. ≈ 3%). 10 Lastly, no data are currently available in regards of VAs incidence in COVID-19 patients with implanted cardiac devices treated conservatively at home. In this regard, it is worth carrying-out such analysis, as experienced in different settings. 11 

In spite of the slight numerical divergence, it is worth noting that the occurrence of VAs consistently clustered with complicated hospitalizations, suggesting that ventricular arrhythmias are a marker of severe systemic disease. 7,10 Indeed, besides anecdotic cases of VAs survivors, 2, 3, 4, 6 the mortality at one month is substantially higher in patients experiencing arrhythmias of ventricular nature (VT or ventricular fibrillation [VF], 59% vs. 16% in controls; p<0.001, respectively). 10 On the contrary, non-sustained episodes of VAs do not seem to predict mortality within the year. 7 Furthermore, another detailed breakdown of the relationship between VAs and clinical outcomes argues against the role of malignant ventricular tachycardias as the primary/initial cause of death.

For instance, as reported by two different groups, a non-shockable rhythm was the predominant cause of cardiac arrest/death (90% in both studies). 7, 12 Correspondingly, in a series of 140 patients admitted on telemetry monitor, fatal VAs were noted in only 12% deceased patients (6/52). 12 All the events were represented by VF, one patient survived, and two autopsy exams suggested that the initial cause of death was pulmonary rather than a cardiac.

The prevalence and clinical significance of premature ventricular contractions (PVCs) in the setting of acute infection were less investigated: although subjects with SARS-CoV-2 infection can initially complain of palpitations (7%), 13 dedicated analysis is scarce. An Italian study showed that 4% (n=13/324) of COVID-19 positive subjects admitted to the emergency department presented ventricular ectopy, 14 compared to 13% of 1053 hospitalized patients (n=137). 10 Despite the evidence that PVCs are seen in cases of novel coronavirus related myocarditis, 15,16 the positive predictive value for cardiac involvement is poor, 17 and likewise the association with mortality is borderline (HR= 2.79, 95%CI: 1.00-7.79, p= 0.051). 14 

A broad number of articles discuss the possible causes of VAs during acute COVID-19. For the sake of simplification, herein we distinguish between intrinsic and extrinsic causes, depending upon the direct or indirect role of the pathogen agent. The formers can be divided into two types: primary intrinsic (directly due to the interaction between the virus and the cardiomyocyte) and secondary intrinsic (after the immune response to the systemic infection, Figure 1) . Overall, rarely a single factor can be pointed as the source of VA; instead, plural elements could affect the electrical vulnerability of the ventricles. 18 

A brilliant in vitro model showed that infected cardiomyocytes derived from a human pluripotent staminal cell exhibit a significant reduction contractile activity measured as beats per minute (4 vs. 9 in controls) and a greater extent of contraction dis-synchrony compared to mock SARS-CoV-2 negative cultures. 19 Such effect became even more prominent after 48 hours of treatment with interleukin-6. In fact, even though the presence of the virus in cardiac tissue or evidence of myocarditis have been inconsistently detected, 20, 21, 22 cytokines surge from the systemic immune response are alone sufficient to dysregulate calcium handling, modulate ion channels expression, increase fibrosis and exert a negative inotropic effect, ultimately enhancing the susceptibility to VAs. 23, 24, 25, 26, 27 For example, late VAs and epicardial fibrosis at the magnetic resonance were documented in one case months after the resolution of the acute illness. 28 J o u r n a l P r e -p r o o f COVID-19 can provoke cardiac ischemia as well, due to both hypoxia/demanding mechanism, 29 but also as it can eminently be thrombogenic and cause coronary micro-emboli and acute coronary syndromes (ACS). 30, 31 The relationship with sustained VAs, however, does not differ from negative controls admitted with ACS (4.9% vs. 6.8%, p=ns). 32 Beyond the direct involvement of the heart, systemic metabolic derangement such as acidosis, hypercapnia, hypokalemia, dehydration, and catecholamines surge do precipitate VAs. 33, 34, 35, 3637 Also, fever can incidentally unmask Brugada pattern in predisposed subjects, 5, 6 and obviously, patients with pre-existing cardiomyopathy are more prone to develop VAs in the setting of SARS-CoV-2 infection. 2,12

VAs can also be iatrogenic. Based on the evidence that hydroxychloroquine and chloroquine inhibit lysosome turnover, and consequently the antigen presentation initiating the immune response, 38 there has been a large empirical use of antimalarial drugs at the beginning of the pandemic with the purpose to damper the adverse events and the hospitalization duration.

However, the most concerning side effects of hydroxychloroquine are QT prolongation and TdP, especially if combined with antimicrobial prophylaxis with azithromycin or lopinavir/ritonavir. 39, 40 Indeed, the duration of phase 2 of the action potential is prolonged through hydroxychloroquine inhibition of the hERG channels, slowing the potassium rapid inward currents (iKr), and by means of sodium current enhancement exerted by azithromycin on SC5NA. 41, 42, 43 Repolarization prolongation by 10-50 ms is relatively frequent (5-50%), 12,39.40,44 and in one series of 201 patients treated with empirical prophylaxis, 18 (11%) developed QTc prolongation >500 ms, albeit only one patient had sustained VT (0.5%), and no TdP was recorded. 39 In another series, no difference in VAs incidence was seen between patients treated with antimalarial agents versus controls, 12 while Gasparetti et al. concluded that the 3 VF in 28 patients admitted in ICU (10%) was due to ongoing ACS and not to hydroxychloroquine induced QT. 40 Therefore, QT prolongation inconsistently predicts VAs in COVID-19 patients, 3,12,40 likewise hydroxychloroquine is rarely associated with malignant arrhythmias (<1%). 10, 39, 44 ST-T wave changes seemingly are not related to VAs 45 ; however, elevated markers of cardiac injury (troponin, natriuretic peptide) and systemic inflammation (i.e., C-reactive protein, interleukin-6) are significantly higher in patients presenting life-threatening arrhythmias, 3, 8, 9, 46, 47 nonetheless it is not univocally acknowledged. 12 Differently, a high dose of pressors seems to correlate with VAs J o u r n a l P r e -p r o o f incidence, both due to adrenergic stimulation and also for an implication of severe cardiogenic shock, whereas the value of admission left ventricular function is controversial. 8, 10, 12, 12, 15, 46 

If supportive management, including correction of electrolyte and acid/base derangement, fluid repletion, blood transfusion, coronary or pulmonary reperfusion, is not adequate, rationale antiarrhythmic strategies should be adopted. Sedatives and anaesthetics should be titrated down or discontinued when identified as the cause of bradycardia or QT prolongation, 4 and standard dose of beta-blockers is certainly useful compatibly with the cardiac output.

Thirty-four percent of the 447 respondents (n=150) to a global survey (March-April 2020) admitted to using amiodarone for VAs treatment, while 15% (n=64) disclosed having used lidocaine or mexiletine for the same purpose. Other class III agents (sotalol and dofetilide) were rarely reported. 48 Pulmonary and hepatic toxicity probably refrained most physicians from adopting amiodarone in secondary prevention in patients with concomitant viral respiratory syndrome often complicated by liver dysfunction. 49 According to some authors, lung toxicity is more likely to occur in ICU patients in which the oxidative damage of high oxygen partial pressure potentiates the free radicals derived from the iodine accumulated in the alveoli. 50 However, it worth highlighting that acute lung toxicity is an adverse event reported anecdotally; 51,52 rather a cumulative dose of 150 grams, 400 mg daily for three months or 200 mg for more than eighteen months are associated with pulmonary injury. 53, 54, 5556 On the contrary, liver toxicity requires as high as 300 grams of cumulative dose, 57 but according to some German scholars, one third of the SARS-CoV-2 patients admitted in ICU has shock liver, which may compromise amiodarone metabolism. 49 In our opinion, the vast experience in daily practice and the existing literature in non-COVID scenarios is more than sufficient to state that amiodarone is efficacious for malignant arrhythmias in COVID-19 patients. Despite isolated warning reports about lung and hepatic toxicity in some subjects with new coronavirus infection, 58, 59, 60 the legitimate concern should be the risk of liver injury and of QT prolongation secondary to drug-drug interaction with antimicrobials; 39,44 thus, we think that amiodarone should be cautiously dosed in patients with extreme transaminitis, but J o u r n a l P r e -p r o o f still be preferred to other more torsadogenic class III agents. Furthermore, in the case of long QT (>550 ms), the treatment should switch to Ib agents, which can shorten the repolarization. 61 Interestingly, amiodarone exhibits pleiotropic effects that can interfere with SARS-CoV-2 infection, by altering the ion channels of the endosomal vesicles. 62 Also, it prevents cytokines production supposedly through the same mechanism in lymphocytes in vivo, 63 and additionally presents scavenging effects of on oxygen free radicals in vitro. 64 In light of such anti-inflammatory antioxidant properties, amiodarone has been proposed for the treatment of symptomatic patients; besides a single case report, 65 a randomized trial in comparison with verapamil is currently on recruiting (ReCOVery-SIRIO, ClinicalTrials.gov identifier: NCT04351763). 66, 67 ICDs and endocardial ablation should be recommended in agreement with the international guidelines, 68, 69, 70 and when available, a remote navigation system should be used for the ablation to minimize the exposure of the medical staff. 2

SARS-CoV-2 is a systemic disease that can also impair the electrical stability of the ventricles.

Although a direct cardiac infection by the virus is plausible, the host's systemic neuroinflammatory response in addition to metabolic disorders are the main triggers of VAs. The physician should be aware that subjects with pre-existing cardiac disease, admitted to ICU, requiring pressor support are more at risk of developing malignant arrhythmias. Therefore, strict monitoring of drugs interactions and precipitating factors (such as hypoxemia, hypokalemia, acidosis) is essential for primary prevention. Amiodarone is generally safe for the secondary prophylaxis of sustained events, and also might show unexplored antiviral/antinflammatory effects in human. Intravenous procainamide, lidocaine or oral mexiletine are alternatives, albeit the evidence is limited. Contrarily, sotalol and dofetilide should be discouraged, since the more significant torsadogenic effect can be detrimental in such a delicate scenario. Lastly, substrate ablation is recommended in case of refractory episodes, when possible using a remote navigation system to minimize the contact with the providers. --bradycardia induced tachyarrhytmias secondary to sedation 3

Ventricular tachycardia storm management in a COVID-19 patient: a case report

Ventricular Fibrillation Storm in Coronavirus

Electrical Storm in COVID-19. JACC Case Rep

COVID-19 infection unmasking brugada syndrome

Fan R Medication unmasked Brugada syndrome and cardiac arrest in a COVID-19 patient. HeartRhythm Case Rep

COVID-19 and cardiac arrhythmias

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Cardiac arrhythmias in critically ill patients with coronavirus disease 2019: A retrospective population-based cohort study

Arrhythmic Complications of Patients Hospitalized With COVID-19: Incidence, Risk Factors, and Outcomes

device follow-up in COVID-19 pandemic: Lessons learned during Italian lockdown

Malignant Arrhythmias in Patients With COVID-19: Incidence, Mechanisms, and Outcomes

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

Electrocardiographic findings at presentation and clinical outcome in patients with SARS-CoV-2 infection

The Spectrum of COVID-19-Associated Myocarditis: A Patient-Tailored Multidisciplinary Approach

Coronavirus-induced myocarditis: A metasummary of cases. Heart Lung

Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management

Novel perspectives on arrhythmia-induced cardiomyopathy: pathophysiology, clinical manifestations and an update on invasive management strategies

Evidence of SARS-CoV-2 Transcriptional Activity in Cardiomyocytes J o u r n a l P r e -p r o o f of COVID-19 Patients without Clinical Signs of Cardiac Involvement

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease

Effects of cytokines and nitric oxide on myocardial E-C coupling

Systemic inflammation as a novel QT-prolonging risk factor in patients with Torsades de Pointes

Sickle cell disease, interleukin-18, and arrhythmias

Proinflammatory Cytokine Modulates Intracellular Calcium Handling and Enhances Ventricular Arrhythmia Susceptibility. Front Cardiovasc Med

Variant of ventricular outflow tract ventricular arrhythmias requiring ablation from multiple sites: Intramural origin. Heart Rhythm

Ventricular tachycardia with epicardial and pericardial fibrosis 6 months after resolution of subclinical COVID-19: a case report

COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors; Heart Rhythm

Evidence of systemic endothelial injury J o u r n a l P r e -p r o o f and microthrombosis in hospitalized COVID-19 patients at different stages of the disease

Microthrombi as a Major Cause of Cardiac Injury in COVID-19: A Pathologic Study

Impact of COVID-19 pandemic and infection on in hospital survival for patients presenting with acute coronary syndromes: A multicenter registry

Myocardial ischemia and ventricular fibrillation: pathophysiology and clinical implications

Hypokalemia Promotes Arrhythmia by Distinct Mechanisms in Atrial and Ventricular Myocytes

Studies on cardiac arrest: the relationship of hypercapnia to ventricular fibrillation

Electrolyte abnormalities underlying lethal and ventricular arrhythmias

Simple electrocardiographic criteria for rapid identification of wide QRS complex tachycardia: The new limb lead algorithm. Heart Rhythm

Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology

Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection

Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings

Electrophysiologic Studies on the Risks and Potential Mechanism Underlying the Proarrhythmic Nature of Azithromycin

Chloroquine blocks the Kir4.1 channels by an open-pore blocking mechanism

Azithromycin Causes a Novel Proarrhythmic Syndrome

QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin

T-wave inversion as a manifestation of COVID-19 infection: a case series

COVID-19, Arrhythmic Risk, and Inflammation: Mind the Gap! Circulation

Predictors and Prognostic Implications of Cardiac Arrhythmias in Patients Hospitalized for COVID-19

COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies

Severe liver dysfunction complicating course of COVID-19 in the critically ill: multifactorial cause or direct viral effect? Ann Intensive Care

Is amiodarone an underrecognized cause of acute respiratory failure in the ICU?

Acute fatal post-CABG low dose amiodarone lung toxicity. Asian Cardiovasc Thorac Ann

Rapid onset of amiodarone induced pulmonary toxicity after lung lobe resection -A case report and review of recent literature

Pulmonary Toxicity in Patients Receiving Low-Dose Amiodarone

Amiodarone-induced pulmonary toxicity with an excellent response to treatment: A case report

III Amiodarone pulmonary toxicity

Amiodarone-induced cirrhosis of liver: What predicts mortality? ISRN Cardiol

Case report of amiodarone-associated allergic pneumonitis amidst the COVID-19 pandemic

Amiodarone in COVID-19: let's not forget its potential for pulmonary toxicity

The Liver in COVID-19-Related Death: Protagonist or Innocent Bystander?

An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine

Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level

Amiodarone inhibits interleukin 6 production and attenuates myocardial injury induced by viral myocarditis in mice

Amiodarone protects cardiac myocytes against oxidative injury by its free radical scavenging action

Safety and Efficacy of Amiodarone in a Patient With COVID-19. JACC Case Rep

Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?

LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: Executive summary

ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)

Long-term outcomes of different ablation strategies for ventricular tachycardia in